Completed PHASE2 INTERVENTIONAL NCT00002131
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
Sponsor: Otsuka America Pharmaceutical
Conditions
HIV Infections Sarcoma, Kaposi
Interventions
Vesnarinone
Updated 5 times since 2017 Last updated: Jun 23, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on HIV Infections and Sarcoma, Kaposi, this trial is completed. The trial is conducted by Otsuka America Pharmaceutical and has accumulated 5 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Otsuka America Pharmaceutical
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .